Meanwhile, the European Commission is also playing its part in the scrutiny of the pharma sector. It recently imposed a EUR 60.5 million pay-for-delay fine, accepted commitments for excessive pricing and is investigating potential anticompetitive conduct of pharmaceutical company Teva. The appeal by drug manufacturer and originator company Servier against the General Court's ruling on its patent settlement agreements is also pending (see our January 2019 newsletter).